Accelerate biotechnology

Scientific publication: Formulation development live rotavirus vaccine candidate for use low- and middle-income countries

We are proud to announce a third publication coming from our rotavirus vaccine project, funded by the Bill & Melinda Gates Foundation. The peer-reviewed journal Human Vaccines & Immunotherapeutics has published scientific data generated together with the University of Kansas on the formulation development of a live-attenuated, human neonatal rotavirus vaccine candidate (RV3-BB). The three…


Article: Interview Menzo Havenga on Future of Vector Vaccines

Now that the mRNA-based SARS-CoV-2 vaccines turn out to be successful, is there still a future for vector-based vaccines? “Absolutely”, says expert Menzo Havenga (CEO, Batavia Biosciences). In an interview with a Dutch local newspaper, Menzo explains some of the benefits of the use of viral vectors, such as the stability and costs. Additionally, viral…


Scientific publication: STEP® vectors for rapid generation of stable CHO cell lines for difficult-to-express proteins

Many proteins produced in CHO cells need evaluation for their clinical and commercial potential. Traditional methods based on stable clone generation are slow and unsuitable for screening larger numbers of proteins, while transient expression technologies are fast but unpredictable regarding product quality and lacking an optional path to subcloning. Therefore, we developed an alternative and…


Blog: How to work with a CDMO for viral vectors: 5 steps to success

Viral vector technologies are at the heart of many promising new therapies, such as vaccines, gene therapies, immune-oncology therapies and other advanced therapy medicinal products (ATMPs). In this rapidly evolving and competitive landscape, there is little scope for error or inefficiency in the development process. A contract manufacturing and development organization (CDMO) that specializes in…


Blog: Accelerating viral vector and vaccine development: beware the pitfalls of scale-up

You’ve developed a candidate viral vaccine or viral vector product, and initial preclinical data are showing excellent efficacy. Now you’re ready to scale up for IND application and testing in human subjects…or are you? Whether you are developing a viral vaccine, cancer vaccine, oncolytic virus, gene therapy or other viral vector application, the choices you…


Article: How we prepare for the next virus outbreak

Recently, Menzo Havenga (CEO at Batavia Biosciences) was interviewed by the online magazine named “Startup Info”. This magazine is devoted to informing its readers on the booming startup ecosystem worldwide. The magazine desires to provide entrepreneurs who are looking for inspiration with relevant information, tips, and tricks. In the interview, Menzo elaborates on the impact…


Scientific publication: Process development for cost-effective, liquid rotavirus vaccine

We are proud to announce that our recent manuscript has been accepted for publication in the journal Vaccine. The manuscript describes the development of a low-cost manufacturing process for a novel human rotavirus vaccine.  Rotavirus infection, associated with severe vomiting and diarrhea, is a leading cause of mortality in young children. Despite the presence of…


COVID-19 Message

Please read the message from our executive management regarding the precautionary measures at Batavia Biosciences.